Fig. 1
Lysate/CpG treatment protects from live tumor challenge and delays growth of existing neuroblastoma. a Groups of mice (6–8 per group) received 2 weekly hind flank sc treatment of AgN2a tumor lysate, CpG, AgN2a lysate mixed with CpG or no treatment. Mice were challenged with 105 AgN2a FF cells 10 days after the last treatment and were followed for tumor growth. Mice were euthanized when tumor growth exceeded 250 mm2. The graph represents 1 of 2 separate experiments. The CpG only group was tested once with 8 mice per group. b Mice received 105 AgN2a FF cells sc in the hind flank. Beginning 9 days after tumor inoculation, mice received no treatment or 4 weekly treatments of lysate/CpG. In addition to lysate/CpG, some mice received 200 μg of anti-Thy1.2 antibody ip on days 14, 18, 22 and 26. Mice were followed for survival and euthanized when tumor size reached 250 mm2. The graph represents combined data from 2 experiments with 5 mice per group. Data was analyzed for statistical significance using the log-rank (Mantel-Cox) test